Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial

BackgroundIn this trial, we aimed to assess the efficacy and safety of radiotherapy with nedaplatin or cisplatin in patients with locally advanced cervical cancer.MethodsWe conducted an open-label, non-inferiority, phase III, randomized, controlled trial. Eligible patients with stage IIB-IVA cervica...

Full description

Bibliographic Details
Main Authors:	Shasha He, Yan Wang, Yulin Lai, Xinping Cao, Yufeng Ren, Yong Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Oncology
Subjects:	cervical carcinoma nedaplatin cisplatin toxicity survival
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.798617/full

Similar Items

Hypomagnesemia because of nedaplatin for cervical cancer: A case report
by: Jun Komoda, et al.
Published: (2023-07-01)

Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma
by: Peng PJ, et al.
Published: (2015-12-01)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)

The Influence of Cisplatin Dose upon Survival in Concurrent Chemoradiotherapy of Locally Advanced Cervical Carcinoma with Weekly Cisplatin
by: Igor Sirák, et al.
Published: (2008-01-01)

Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin
by: Kenro Chikazawa, et al.
Published: (2020-07-01)

Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
by: W.J. Sheng, et al.
Published: (2013-08-01)

Case Report: Etoposide-nedaplatin induced rhabdomyolysis in a small cell lung cancer patient
by: Xiaohu Xu, et al.
Published: (2023-08-01)

Successful nedaplatin desensitization therapy in a patient with platinum-sensitive recurrent ovarian cancer: A case report and literature review
by: Tetsuya Kokabu, et al.
Published: (2022-10-01)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
by: Hirokazu Taniguchi, et al.
Published: (2019-09-01)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
by: Qiuji Wu, et al.
Published: (2021-10-01)

Encapsulation of Nedaplatin in Novel PEGylated Liposomes Increases Its Cytotoxicity and Genotoxicity against A549 and U2OS Human Cancer Cells
by: Salma El-Shafie, et al.
Published: (2020-09-01)

Nedaplatin as a Single-Agent Chemotherapy May Support Palliative Therapy for Patients with Adenoid Cystic Carcinoma: A Case Report
by: Hiroyuki Hirakawa, et al.
Published: (2017-08-01)

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial
by: Yan Wang, et al.
Published: (2022-11-01)

Enhanced Anticancer Activity of Nedaplatin Loaded onto Copper Nanoparticles Synthesized Using Red Algae
by: Nada Mostafa Aboeita, et al.
Published: (2022-02-01)

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma
by: Kailin Wang, et al.
Published: (2019-05-01)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
by: Xi-Lei Zhou, et al.
Published: (2021-05-01)

Propensity score matching analysis to comparing cisplatin versus nedaplatin based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer
by: Yue Zhang, et al.
Published: (2023-06-01)

Conventional chemoradiation with Cisplatin Versus hemoradiation with Cisplatin plus Gemcitabine in uterine cervical cancer
by: Ahmad Ameri (MD), et al.
Published: (2008-10-01)

Concurrent weekly single cisplatin vs triweekly cisplatin alone with radiotherapy for treatment of locally advanced cervical cancer: a meta-analysis
by: Zhu J, et al.
Published: (2018-07-01)

Treatment outcomes of concurrent weekly cisplatin with intracavitary brachytherapy in patients with cervical carcinoma, pre-treated with concurrent chemo-radiotherapy
by: Swapan K Mallick, et al.
Published: (2022-01-01)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
by: Takuma Kagami, et al.
Published: (2020-11-01)

Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial
by: Jing Li, et al.
Published: (2022-01-01)

Correlation of CTR1, ERCC-1, and HSP70 expressions with cisplastin response in cervical cancer stage IIB
by: Brahmana Askandar, et al.
Published: (2020-01-01)

Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer
by: Narayan Rajan, et al.
Published: (2014-12-01)

Nedaplatin/<i>Peganum harmala</i> Alkaloids Co-Loaded Electrospun, Implantable Nanofibers: A Chemopreventive Nano-Delivery System for Treating and Preventing Breast Cancer Recurrence after Tumorectomy
by: Nada K. Sedky, et al.
Published: (2023-09-01)

Survival and toxicity outcomes of induction chemotherapy followed by concurrent chemoradiotherapy compared with concurrent chemoradiotherapy alone in inoperable stage III and IVA/B head and neck cancer
by: Sajib Kumar Talukdhar, et al.
Published: (2022-03-01)

Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer
by: Lekha Madhavan Nair, et al.
Published: (2017-01-01)

The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer
by: Rina Masadah, et al.
Published: (2021-03-01)

Clinical outcomes observation in stage IIB–IIIB cervical cancer treated by adjuvant surgery following concurrent chemoradiotherapy
by: Yong Li, et al.
Published: (2021-04-01)

Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma
by: Xin-Bin Pan, et al.
Published: (2024-01-01)

Efficacy of cisplatin-based combinations in chemoradiation therapy of cervical cancer
by: I Ya Bazaeva, et al.
Published: (2015-09-01)

"STUDY OF CONCURRENT CISPLATIN AND EXTERNAL RADIOTHERAPY PRIOR TO RADICAL HYSTERECTOMY AND LYMPHADENECTOMY IN PATIENTS WITH STAGE IB-IIB CERVICAL CANCER"
by: M. Modares Gilani, et al.
Published: (2004-06-01)

"STUDY OF CONCURRENT CISPLATIN AND EXTERNAL RADIOTHERAPY PRIOR TO RADICAL HYSTERECTOMY AND LYMPHADENECTOMY IN PATIENTS WITH STAGE IB-IIB CERVICAL CANCER"
by: M. Modares Gilani, et al.
Published: (2004-04-01)

Graphene Oxide Enhanced Cisplatin Cytotoxic Effect in Glioblastoma and Cervical Cancer
by: Kacper Kregielewski, et al.
Published: (2023-08-01)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
by: Hundo Cho, et al.
Published: (2022-05-01)

RPL24 as a potential prognostic biomarker for cervical cancer treated by Cisplatin and concurrent chemoradiotherapy
by: Cheng Ming, et al.
Published: (2023-10-01)

MicroRNA-217 Acts as a Tumor Suppressor and Correlates with the Chemoresistance of Cervical Carcinoma to Cisplatin [Retraction]
by: Yin Z, et al.
Published: (2023-06-01)

Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy
by: Xin Li, et al.
Published: (2023-10-01)

Comparison of Tumor Regression Rate in Cervical Cancer Patients Treated with Radiotherapy Alone versus Chemoradiotherapy
by: Orkhan Galib DUNYAMALIYEV, et al.
Published: (2010-04-01)

Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy
by: Santu Saha, et al.
Published: (2022-09-01)